U.S. Markets open in 6 hrs 40 mins

Johnson & Johnson’s Recent Development in HIV

Sarah Collins
Johnson & Johnson’s Recent Development in HIV

On August 15, Johnson & Johnson (JNJ) and ViiV Healthcare, the HIV business subsidiary of GlaxoSmithKline (GSK), announced positive top-line results of their Phase 3 ATLAS (Antiretroviral Therapy as Long-Acting Suppression) trial. The regimen consists of Johnson & Johnson’s rilpivirine and ViiV Healthcare’s cabotegravir, which is injected once per month. The study evaluated this 2DR therapy with the standard of care three-drug daily oral regimen.